Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Charles University, Czech Republic
With
General University Hospital, Prague
Patients newly diagnosed with DLBCL or patients with relapsed DLBCL who consent to participate in this study will apart from standard staging and restaging examination with PET/CT undergo whole-body MRI (wbMRI). From blood samples, the level of circulating tumor DNA (ctDNA) fragments will be estimated. These procedures will be repeated during restaging after primary treatment. The diagnostic accuracy of wbMRI in initial staging and restaging will be compared with PET/CT as the gold standard. Circulating tumor DNA levels will be compared at baseline with staging from PET/CT. The change in levels of ctDNA will be compared with the treatement response assessed by PET/CT. All three methods will be used as prognostic indicators.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
age ≥18 years
performance status according to the Eastern Cooperative Oncology Group between 0 and 3
satisfactory clinical condition to participate in this study
adequate hematologic and renal functions
no contraindications to MRI
recent or planned PET/CT at the institution
informed consent to participate.
You may not be if
history of indolent lymphoma
anti-lymphoma treatment initiated before PET/CT or wbMRI
central nervous system lymphoma
Clareo Health | Comparison of Whole-body MRI, Circulating DNA and PET-CT in Staging, Prognosis, and Treatment Response in Patients with Diffuse Large Cell B Lymphoma
